Hikma Pharmaceuticals PLC
NYSE
Hikma Pharmaceuticals PLC's latest marketcap:
As of 06/09/2025, Hikma Pharmaceuticals PLC's market capitalization has reached $6.36 B. According to our data, Hikma Pharmaceuticals PLC is the 2712th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 6.36 B |
| Revenue (ttm) | 3.39 B |
| Net Income (ttm) | 388.98 M |
| Shares Out | 220.43 M |
| EPS (ttm) | 1.74 |
| Forward PE | 12.49 |
| Ex-Dividend Date | 03/20/2025 |
| Earnings Date | 08/07/2025 |
Hikma Pharmaceuticals PLC's yearly market capitalization.
| Date | Market Cap | Change (%) |
|---|---|---|
| 06/09/2025 | £4.69 B | 6.14% |
| 12/31/2024 | £4.42 B | 11.74% |
| 12/29/2023 | £3.96 B | 15.72% |
| 12/30/2022 | £3.42 B | -33.45% |
| 12/31/2021 | £5.14 B | -11.5% |
| 12/31/2020 | £5.8 B |
Company Profile
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC is a global pharmaceutical company specializing in the development, manufacturing, and marketing of generic, branded, and in-licensed pharmaceutical products. Founded in 1978 and headquartered in London, UK, the company serves markets across Europe, North America, the Middle East, North Africa, and other international regions.
Business Segments
- Injectables: Provides generic and specialty injectable products, primarily for hospital use.
- Generics: Offers oral, respiratory, and other generic and specialty products tailored for the retail market.
- Branded: Supplies branded generics and in-licensed products to both retail and hospital markets.
Therapeutic Areas & Product Forms
Hikma Pharmaceuticals delivers treatments across multiple therapeutic areas, including:
- Respiratory
- Oncology
- Pain Management
Products are available in various dosage forms, such as:
- Solid
- Semi-solid
- Liquid
- Injectable
Frequently Asked Questions
-
What is Hikma Pharmaceuticals PLC's (LON-HIK) current market cap?As of 06/09/2025, Hikma Pharmaceuticals PLC (including the parent company, if applicable) has an estimated market capitalization of $6.36 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Hikma Pharmaceuticals PLC (LON-HIK) rank globally by market cap?Hikma Pharmaceuticals PLC global market capitalization ranking is approximately 2712 as of 06/09/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.